DATE/TIME
September 19, 09:00 – 09:30 AM EST
TOPIC
Biomanufacturing 2025: What’s Driving the Next Wave of Outsourcing Growth
SPEAKER
Eric Langer
President and Managing Partner
BioPlan Associates, Inc.
ABSTRACT
As the biomanufacturing landscape continues to evolve, outsourcing is playing an increasingly critical role in driving growth and innovation. This session will explore the key market forces shaping biomanufacturing in 2025, including shifting sponsor-CDMO dynamics, global supply chain considerations, and the impact of emerging technologies. Attendees will gain insights into the trends fueling the next wave of outsourcing and what they mean for the future of drug development and commercialization.
BIO
Eric has over 25 years of experience in life sciences market assessment, valuation, marketing, management, and publishing. He has served as a senior manager at biopharmaceutical supply companies and is an experienced biotechnology strategist. His team has advised hundreds of companies on marketing strategy, valuation, pricing, and messaging, developing strategic plans based on quantitative analysis of market trends and buyer needs.
He teaches graduate-level biotechnology marketing at Johns Hopkins University and biomedical valuation at the NIH Graduate School.
For decades, Eric’s team has evaluated contract and outsourced bioprocessing services spanning discovery, bioproduction, assay development, and fill-finish. He has authored numerous articles and book chapters on outsourcing, offshoring, supply chain security, and innovative service technologies. His team has provided due diligence support and market research for major bioprocess service providers, assessing the viability of novel offerings. BioPlan has also analyzed offshoring opportunities in emerging economies such as China, India, and Latin America, and has developed CDMO databases for over 20 years, including Top300CDMO.com and other resources profiling current service suppliers.
